Myrtleciclib
Alternative Names: Myrtleciclib - ViroStatics; VS 2370; VS2-370 - Virostatics/Vichem ChemieLatest Information Update: 25 Feb 2025
At a glance
- Originator Vichem Chemie
- Developer Virostatics
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Cyclin-dependent kinase 9 inhibitors; Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I Cancer; HIV infections
Most Recent Events
- 25 Feb 2025 Phase-I clinical trials in Cancer (PO), prior to February 2025 (Vichem Chemie pipeline, February 2025)
- 25 Feb 2025 Phase-I clinical trials in HIV infections (PO), prior to February 2025 (Vichem Chemie pipeline, February 2025)
- 17 Jun 2024 Virostatics has patent protection for Myrtleciclib worldwide, prior to June 2024 (Virostatics pipeline, June 2024)